A novel drug produced in CHO cells has recently been approved by the FDA

Tislelizumab-jsgr is a PD-1 blocking antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.
👉 As CHO cells continue to play an extremely important role in the manufacturing of novel therapeutics addressing an increasing number of medical conditions, we realize how much their role in R&D, starting from the discovery early phases can be crucial too.
👉 At Magellan Biologics & Consulting we have developed a solution to make this first R&D step as simple and as efficient as possible. Based on transient gene expression, CHO 4Tx® indeed is a system that includes a dedicated and robust CHO cell line, three media and a highly innovative (patented) protocol. CHO 4Tx® has become a reference in many labs all around the world and our supporting team is always happy to help research scientists and lab managers achieving their goals!
Would you like to know more?
We’re here:
magellanbiologics.com
for you!